Successful therapy for chronic diseases must normalize a targeted aspect of metabolism
without disrupting the regulation of other metabolic pathways essential for maintaining
health. Use of a limited number of single molecule surrogates for disease, or biomarkers, to
monitor the efficacy of a therapy may fail to predict undesirable side effects. In this study, a
comprehensive metabolomic assessment of lipid metabolites was employed to determine
the specific effects of the peroxisome proliferator-activated receptor γ (PPARγ) agonist …